Please enter verification code
Neurochemical Theory of Epilepsy Pathogenesis in It's Neurological and Mental Manifestations
American Journal of Psychiatry and Neuroscience
Volume 8, Issue 2, June 2020, Pages: 33-39
Received: Apr. 23, 2020; Accepted: Jun. 12, 2020; Published: Jul. 4, 2020
Views 369      Downloads 222
Alexander Kharibegashvili, Telavi District Hospital, Telavi State University, Telavi, Georgia
Article Tools
Follow on us
In the article, in light of the hypothesis about the pathogenesis of epilepsy the author considers certain clinical manifestations of epilepsy, touches upon the neurochemistry of behavior, as well as neurotransmitter hypothesis of schizophrenia. According to the hypothesis, in epileptic patients, epileptogenic substances are permanently accumulating in the brain, which in the course of epileptic activity in the brain undergo metabolic changes requiring their removal from the organism. When the concentration of epileptogenic substances in the brain reaches a threshold value, they cause a seizure, and in lower concentrations, they cause epileptic activity typical for the interictal period. In the context of this hypothesis, there are discussed the clinical signs of epilepsy such as forced normalization, reinforcement epilepsy activity during the sleep deprivation and one of the paradoxical effect of antiepileptic drugs such as phenomen when antiepileptic drugs prescribed cause an improvement of the electroencephalographic image but the clinical deterioration and increasing frequency of seizures, and the change of antiepileptic drugs give us the opposite results: improvement of the clinical picture and the deterioration of the electroencephalographic image. According to the supplemented hypothesis, epileptogenic substances, except that, during epileptic activity in the brain undergo metabolic transformations necessary for their removal from the body; there are also alternative transformation neurochemical pathways necessary for their further removal (elimination) from the organism. The hypothesis discusses the modern principles of epilepsy treatment. It was proposed to call the phenomenon “clinical-electroencephalographic dissociation” when the anti-epileptic drugs are associated with the improved electroencephalographic pattern, but with the deterioration of the clinic and frequent seizures, and the drug change leads to the opposite—the improvement of the clinical picture and the EEG deterioration. Forced normalization is considered as one of the manifestations of epilepsy aggravation and “clinical-electroencephalographic dissociation”. When reviewing biological antagonism of schizophrenia and epilepsy the author suggests a hypothesis that if an area of the brain producing epileptogenic substances and an area of the brain producing endogenic psychogenic substances causing psychopathology coexist simultaneously, then, in the event of a generalized convulsive seizure involving the brain in full, epileptogenic as well as psychogenic substances are released. At the same time epilepsy is demonstrated, while schizophrenia is not. The same could be the mechanism of therapeutic activity (effect) of electroconvulsive therapy.
Epilepsy, Neuro Mediators, Forced Normalization of Electroencephalogram Image, Aggravation, Hypothesis, Biological Antagonism of Schizophrenia and Epilepsy, Behavior
To cite this article
Alexander Kharibegashvili, Neurochemical Theory of Epilepsy Pathogenesis in It's Neurological and Mental Manifestations, American Journal of Psychiatry and Neuroscience. Vol. 8, No. 2, 2020, pp. 33-39. doi: 10.11648/j.ajpn.20200802.13
Copyright © 2020 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License ( which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Gabashvili V. M. // Sb. Trudov Tbilisskogo simpoziuma po funktsional'noy neyrokhirurgii. - Tbilisi, 1985. — S. 5-10.
Saradzhishvili P. M., Geladze T. SH. Epilepsiya. — M., 1977.— S. 65-102.
Karlov V. A. Epilepsiya. — M., 1990. — S. 71-115.
Marc A., Dichter M. D. Emerging Concepts in the Pathogenesis of Epilepsy and Epileptogenesis //Arch. Neurol. —2009.—66 (4).—443-447.
Lipatova L. V. Neyroimmunnyye mekhanizmy epilepsii kak klyuch k patogeneticheskomu lecheniyu zabolevaniy // Epilepsiya.—2010.—№3.—S. 20-27.
Page B. Pennell. Hormonal Aspects of Epilepsy //Neurologic Clinics.—2009.—V. 27, Is. 4.—P. 941-965.
Belousova E. D. Trudnosti differentsial'noy diagnostiki epilepsii // Rossiyskiy vestnik perinatologii i pediatrii. -2006.-№6. S. 13.
Stephen G. Waxman Transcriptional channelopathies: An emerging class of disorders //Nature Reviews Neuroscience. —2001.—2.—Р. 652-659.
Joseph G. Bajorek, Randall J. Lee, Peter Lomax. Neuropeptides: A role as endogenous mediators or modulators of epileptic phenomena //Annals of Neurology.—1984.—Vol. 16.—Р. 31-38.
Koide S. Et al. Metabolic profile of opioid peptides differs in the hippocampus and striatum of seizure-susceptible E1 mice //Neurochem. Res.—1995.—Vol. 20.—P. 279.
Astrid G. Chapman Glutamat and epilepsy //J. Nutr.—April 1, 2000.—Vol. 130, № 4.—Р. 1043-1045.
Clements J. D., Lester R. A., Tong G. Et al. The time course of glutamate in the synaptic cleft //Science.—1992.—Vol. 258, № 5087.—P. 1498-1501.
Globus M. Y., Busto R., Dietrich W. D. Et al. Effect of ischemia on the in vivo release of striatal dopamine, glutamate, and gammaaminobutyric acid studied by intracerebral microdialysis //J. Neurochem.—1988.—Vol. 51, № 5.—Р. 1455-1464.
Frandsen A., Schousboe A. Mobilization of dantrolene-sensitive intracellular calcium pools is involved in the cytotoxicity induced by quisqualate and N-methyl-D-aspartate but not by 2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl) propionate and kainate in cultured cerebral cortical neurons //Proc. Natl. Acad. Sci. USA.—1992.—Vol. 89, № 7.—P. 2590-2594.
LeiS. Z., Zhang D., Abele A. E., Lipton S. A. Blockade of NMDA receptor-mediated mobilization of intracellular Ca 2+ prevents neurotoxicity //Brain. Res.—1992.—Vol. 598, № 1–2.—P. 196-202.
Litovchenko T. A. Epilepsiya: terminologiya, epidemiologiya, klassifikatsiya, etiologiya, patogenez //NeyroNews.—2010.—№ 2.—S. 27-33.
Kharibegashvili A. S., Chachiya G. I. K voprosu o patogeneze epilepsii // Mezhdunarodnyy nevrologicheskiy zhurnal. —2012. — № 6 (52).— S. 167-173.
Mukhin K. YU., Pylayeva O. A. Problema aggravatsii epilepticheskikh pristupov na fone terapii antiepilepticheskimi preparatami // Russkaya pochta detskoy nevrologii. — 2014. — №2 (T. IX).— S. 27-33.
Jacqueline A. French. Seizure Exacerbation by Anitiepileptic Drugs //Epilepsy Curr.—2005.—5 (5).—192-193.
Lai Choo Ong. Seizures exacerbated by antiepileptic drugs in children //Neurology Asia.—2010.—15 (Suppl. 1).—Р. 11-12.
Siddhartha Nadkarni, Vanessa Arnedo, Orrin Devinsky. Psychosis in epilepsy patients //Epilepsia.—2007.—Vol. 48, Issue (Suppl. 9).—Р. 17-19.
Krishnamoorthy E. S., Trimble M. R. Forsed Normalization: Clinical and Therapeutic Relevance //Epilepsia.—1999.—40 (Suppl. IO).—Р. 57-64.
Pylayeva O. A., Mukhin K. YU., Petrukhin A. S. Pobochnyye effekty antiepilepticheskoy terapii. — M.: Granat, 2016.
Beth A. Malow. Sleep Deprivation and Epilepsy //Epilepsy Curr.—2004.—4 (5).—Р. 193-195.
Yevtushenko S. K., Omel'yanenko A. A. Klinicheskaya elektroentsefalografiya u detey. — Donetsk: Donechchina, 2005. — 860s.
Yevtushenko S. K., Omel'yanenko A. A. Idiopaticheskiye generalizovannyye epilepsii // Mezhdunarodnyy nevrologicheskiy zhurnal. — 2011. — №6 (44).— S. 56-72.
Litovchenko T. A. Sovremennyye printsipy farmakoterapii epilepsii //NeyroNEWS.—2010.— №5 (24).—S. 32-37.
Kharibegashvili A. S. Yevtushenko S. K.. Ivanova M. F. O vozmozhnykh novykh neyrokhimicheskikh mekhanizmakh patogeneza epilepsii. // Mezhdunarodnyy nevrologicheskiy zhurnal. -2017.-№2 (88). - S. 11-15.
Matthysse S., Sugarman J. Neurotransmitter Theories of Shizophrenia, Handbook of Psychopharmacology, Volume 10, Neuroleptics and Schizophrenia P. 221-242.
Gründer G., Dopamine Hypothesis of Schizophrenia The Neurobiology of Schizophrenia Book.2016, Pages 109-124, Chapter 7.
Clark M. R., Grunstein M. The role of neurotransmitters in human behavior. Are We Hardwired?: The Roles of Genes in Human Behavior P 148-171 Print publication date; 2004 Print ISBN-13; 9780195178005 Published to Oxford Scholarship Online 2010.
Choudhury A., Sahu T. Et al., Neurochemicals, Behaviours and Psychiatric Perspectives of Neurological Diseases Neuropsychiatry (London) (2018) 8 (1) P 396-424.
Veyn A. M. Patogenez tserebral'nykh paroksizmal'nykh sostoyaniy. Plenum Vsesoyuznogo obshchestva nevropatologov i nauchnogo soveta po nevrologii. Materialy. Kiyev. 1991; 12.
Gough J. L, Coebergh J., Chandra B., Nilforooshan R. Electroconvulsive therapy and /or plasmapheresis in autoimmune encephalitis? World Journal of Clinical Cases (WJCC) August 16, 2016|Volume4|Issue8| P 223-238.
Brower Kirk J., Alcohol’s Effects on Sleep in Alcoholics, Alcohol Res Health. 2001; 25 (2): P 110–125.
Cain D. P. Excitatory neurotransmitters in kindling: excitatory amino acid, cholinergic, and opiate mechanisms. NeurosciBiobehav Rev. 1989 Winter; 13 (4): 269-76.
McNamara JO. Role of neurotransmitters in seizure mechanisms in the kindling model of epilepsy. FedProc. 1984 Jul; 43 (10): 2516-20.
Helmstaedter C., Witt J-A. Chapter 10 - Behavioral and neuropsychological aspects of frontal and temporal lobe epilepsy, The Neuropsychiatry of Epilepsy edited by Michael Trimble, Bettina Schmitz Cambridge University Press 2002 P 90-108.
Avedisova A. S. Svyaz' mezhdu shizofreniyey i epilepsiyey: istoriya voprosa i sovremennoye sostoyaniye problemy. Zhurnal: Zhurnal nevrologii i psikhiatrii im. S. S Korsakova. 2016; 116 (9): 126-132.
Huber G, Gross G. The bridges between Neurology and Psychiatry. Neurol Croat. 2003: 52 (suppl2): 65-7.
Gubanova N. B., Karakulova YU. V. Patogeneticheskoye znacheniye serotoninergicheskikh proyavleniy v razvitii idiopaticheskikh generalizovannykh form epilepsii // Byulleten' sibirskoy meditsiny. -2008.-№5.-S. 87-89.
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
Tel: (001)347-983-5186